Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2009 1
2010 2
2011 1
2012 1
2013 2
2014 3
2015 4
2016 4
2017 3
2018 9
2019 9
2020 12
2021 12
2022 11
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ; IMPACT Investigators. Lipson DA, et al. N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18. N Engl J Med. 2018. PMID: 29668352 Free article. Clinical Trial.
BACKGROUND: The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting beta(2)-agonist (LABA), as compared with dual therapy (either inhaled glucocorticoid- …
BACKGROUND: The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting mu …
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P; ETHOS Investigators. Rabe KF, et al. N Engl J Med. 2020 Jul 2;383(1):35-48. doi: 10.1056/NEJMoa1916046. Epub 2020 Jun 24. N Engl J Med. 2020. PMID: 32579807 Clinical Trial.
BACKGROUND: Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting beta(2)-agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been studied at single dose levels of inhaled glucocorticoid, but …
BACKGROUND: Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting beta(2)-a …
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.
Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, Maspero JF, Abdulai RM, Hu CC, Martincova R, Jessel A, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, Goulaouic H. Wechsler ME, et al. N Engl J Med. 2021 Oct 28;385(18):1656-1668. doi: 10.1056/NEJMoa2024257. N Engl J Med. 2021. PMID: 34706171 Clinical Trial.
METHODS: In a phase 2 trial, we randomly assigned, in a 1:1:1:1 ratio, adults with moderate-to-severe asthma receiving inhaled glucocorticoids plus long-acting beta-agonists (LABAs) to receive subcutaneous itepekimab (at a dose of 300 mg), itepekimab plus dupilumab (both at 300 m …
METHODS: In a phase 2 trial, we randomly assigned, in a 1:1:1:1 ratio, adults with moderate-to-severe asthma receiving inhaled glucocorticoi …
2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients With Stable COPD.
Bourbeau J, Bhutani M, Hernandez P, Aaron SD, Beauchesne MF, Kermelly SB, D'Urzo A, Lal A, Maltais F, Marciniuk JD, Mulpuru S, Penz E, Sin DD, Van Dam A, Wald J, Walker BL, Marciniuk DD. Bourbeau J, et al. Chest. 2023 Nov;164(5):1159-1183. doi: 10.1016/j.chest.2023.08.014. Epub 2023 Sep 9. Chest. 2023. PMID: 37690008
Those with moderate to severe dyspnea (modified Medical Research Council 2) and/or impaired health status (COPD Assessment Test 10) and a low risk of exacerbations should receive combination therapy with a long-acting muscarinic antagonist/long-acting SS2-agonist (LAMA/LABA …
Those with moderate to severe dyspnea (modified Medical Research Council 2) and/or impaired health status (COPD Assessment Test 10) and a lo …
The management of mild asthma.
O'Byrne PM, Reddel HK, Beasley R. O'Byrne PM, et al. Eur Respir J. 2021 Apr 8;57(4):2003051. doi: 10.1183/13993003.03051-2020. Print 2021 Apr. Eur Respir J. 2021. PMID: 33093120 Free article. Review.
A golden age of asthma research.
O'Byrne PM, Pavord ID. O'Byrne PM, et al. Eur Respir J. 2020 Dec 24;56(6):2003820. doi: 10.1183/13993003.03820-2020. Print 2020 Dec. Eur Respir J. 2020. PMID: 33361451 Free article. No abstract available.
Factors Predicting Treatment of World Trade Center-Related Lung Injury: A Longitudinal Cohort Study.
Putman B, Lahousse L, Goldfarb DG, Zeig-Owens R, Schwartz T, Singh A, Vaeth B, Hall CB, Lancet EA, Webber MP, Cohen HW, Prezant DJ, Weiden MD. Putman B, et al. Int J Environ Res Public Health. 2020 Dec 4;17(23):9056. doi: 10.3390/ijerph17239056. Int J Environ Res Public Health. 2020. PMID: 33291671 Free PMC article.
Cox proportional hazards models measured the association of high probability of ICS/LABA initiation with actual ICS/LABA initiation in subsequent intervals. ...High-intensity WTC exposure was associated with ICS/LABA between 11 September 2001-10 September 200 …
Cox proportional hazards models measured the association of high probability of ICS/LABA initiation with actual ICS/LABA initi …
Suboptimally controlled asthma in patients treated with inhaled ICS/LABA: prevalence, risk factors, and outcomes.
Zhang S, White J, Hunter AG, Hinds D, Fowler A, Gardiner F, Slade D, Murali S, Meeraus W. Zhang S, et al. NPJ Prim Care Respir Med. 2023 May 8;33(1):19. doi: 10.1038/s41533-023-00336-9. NPJ Prim Care Respir Med. 2023. PMID: 37156824 Free PMC article.
This observational claims-linked survey study assessed the prevalence of and risk factors for suboptimal asthma control and healthcare utilization in adults with asthma receiving fixed-dose combination (FDC) inhaled corticosteroid/long-acting beta(2)-agonist (ICS/LABA). Co …
This observational claims-linked survey study assessed the prevalence of and risk factors for suboptimal asthma control and healthcare utili …
76 results